


# TRAcP (Tartrate-Resistant Acid Phosphatase); Clone ACP5/1070 (Concentrate)


<b>Availability/Contents:</b>	<u>Item #</u>	<u>Volume</u>
	RA0422-C.5	0.5 ml

**Description:**

Species:	Mouse
Immunogen:	Recombinant human ACP5 protein
Clone:	ACP5/1070
Isotype:	IgG2b, kappa
Entrez Gene ID:	54 (Human)
Hu Chromosome Loc.:	19p13.2
Synonyms:	Acid phosphatase 5, tartrate resistant; ACP5; serum band 5 tartrate-resistant acid phosphatase; SPENCDI; Tartrate-resistant acid ATPase; Tartrate-resistant acid phosphatase type 5; TR-AP; TRACP5; TRAcP; TRAP; TrATPase; Type 5 acid phosphatase
Mol. Weight of Antigen:	35kDa
Format:	200µg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide.
Specificity:	This antibody recognizes a protein of 35kDa, which is identified as tartrate-resistant acid phosphatase (TRAcP). It exists as two isoforms (5a and 5b). This antibody reacts with both the isoforms. The anti-TRAcP antibody labels the cells of Hairy Cell Leukemia (HCL) with a high degree of sensitivity and specificity. Other cells stained with this antibody are tissue macrophages and osteoclasts.
Background:	Serum TRAcP 5a is secreted by macrophages and dendritic cells and increased in many patients of rheumatoid arthritis. Serum TRAcP 5b is produced from osteoclasts and elevated during bone resorption. TRAcP is an iron containing glycoprotein, which catalyzes the conversion of orthophosphoric monoester to alcohol and orthophosphate. It is the most basic of the acid phosphatases and is the only form not inhibited by L(+)-tartrate. TRAcP is synthesized as a latent proenzyme and is activated by proteolytic cleavage and reduction. Normally, TRAcP is highly expressed by osteoclasts, activated macrophages, neurons and endometrium during pregnancy. Expression of TRAcP is increased in certain pathological conditions such as Leukemic Reticuloendotheliosis (Hairy Cell Leukemia), Gaucher's Disease, HIV-induced Encephalopathy, Osteoclastoma, and in osteoporosis and metabolic bone diseases.
Species Reactivity:	Human, Mouse, and Rat. Others not known.
Positive Control:	HepG2, 293T, K562 or RPMI-8226 Cells. Spleen from Hairy Cell Leukemia (HCL) patient.
Cellular Localization:	Cytoplasmic (Lysosomes)
Titer/ Working Dilution:	Immunohistochemistry (Frozen and Formalin-fixed): 0.5-1 µg/ml
	Flow Cytometry: 0.5-1 µg/million cells
	Immunofluorescence: 0.5-1 µg/ml
	Western Blotting: 0.5-1 µg/ml
	Immunoprecipitation: 0.5-1 µg/500µg protein lysate
Microbiological State:	This product is not sterile.

 Storage: 2° C  8° C


 ScyTek Laboratories, Inc.  
 205 South 600 West  
 Logan, UT 84321  
 U.S.A.



 EmergoEurope (31)(0) 70 345-8570  
 Molsnstraat 15  
 2513 BH Hague, The Netherlands

**Uses/Limitations:** Not to be taken internally.  
For Research Use Only.  
This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissue sections, to be viewed by light microscopy.  
Do not use if reagent becomes cloudy.  
Do not use past expiration date.  
Non-Sterile.

**Ordering Information and Current Pricing at [www.scytek.com](http://www.scytek.com)**

**Procedure:**


1. **Tissue Section Pretreatment (Required):** Staining of formalin fixed, paraffin embedded tissue sections is significantly enhanced by pretreatment with Citrate Plus (ScyTek catalog# CPL500).
2. **Primary Antibody Incubation Time:** We suggest an incubation period of 30 minutes at room temperature. However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
3. **Visualization:** For maximum staining intensity we recommend the “UltraTek HRP Anti-Polyvalent Lab Pack” (ScyTek catalog# UHP125, see IFU for instructions) combined with the “DAB Chromogen/Substrate Bulk Pack (High Contrast)” (ScyTek catalog# ACV500, see IFU for instructions).


**Precautions:** Contains Sodium Azide as a preservative (0.09% w/v).  
Do not pipette by mouth.  
Avoid contact of reagents and specimens with skin and mucous membranes.  
Avoid microbial contamination of reagents or increased nonspecific staining may occur.  
This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200, OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

**References:**

1. Fleckenstein, E.C., Dirks, W.G. and Drexler, H.G. 1996. Cloning and characterization of the human tartrate-resistant acid phosphatase (TRAP) gene. *Leukemia* 10: 637-643.
2. Capeller, B., Caffier, H., Sütterlin, M.W. and Dietl, J. 2003. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. *Anticancer Res.* 23: 1011-1015.


**Warranty:** No products or “Instructions For Use (IFU)” are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used.

Storage: 2° C  8° C



ScyTek Laboratories, Inc.  
205 South 600 West  
Logan, UT 84321  
U.S.A.



 EmergoEurope (31)(0) 70 345-8570  
Molsnstraat 15  
2513 BH Hague, The Netherlands